User Experience Specialist - Information Systems
About the job
- A doctorate degree, or a master's degree, bachelor's degree, or diploma with 8–13 years of experience in Computer Science, Business, Engineering, Information Technology, or Supply Chain.
- Proficiency with standard design and wireframing tools, including Figma, hand drawing, whiteboarding, visual communication, and interactive prototyping tools such as Figma Prototyping and Miro.
- Experience building responsive desktop, web, and mobile applications.
- Deep knowledge of user interface and user experience best practices, accessibility standards, and design patterns.
- Ability to lead design workshops, articulate design decisions, and update designs based on stakeholder feedback.
- Ability to lead and mentor designers, build teams, and connect with designers across teams.
- Experience with Figma design systems and using components within Figma.
- Excellent analytical troubleshooting, verbal and written communication, presentation, and public speaking skills.
- Proactive problem-solving skills and timely participation in team meetings and Scrum ceremonies.
- Balance user goals, business requirements, and technical feasibility to deliver simple and elegant designs as part of a product team.
- Lead the experience design process for digital products from concept through execution.
- Lead design discussions with product managers and business leads to define user requirements and design goals.
- Provide design leadership, guidance, and mentorship to designers while communicating business requirements and user needs.
- Collaborate with developers to create technically feasible design solutions that ensure an optimal user experience.
- Contribute to UX strategy and understand the long-term roadmap for tools and platforms.
- Design UX flows for data products, dashboard interfaces, and operational tools built on React, Angular, Tableau, and generative artificial intelligence platforms.
- Create annotated prototypes and wireframes that communicate the intended behavior of software applications visually and textually.
- Lead and influence business-wide discussions about current user experience projects and the future direction of design and user experience.
- Design conversational experiences and user interface workflows integrated with natural language and large language model-driven analytics assistants.
- Use Figma to create wireframes, prototypes, and visual designs.
- Use Jira to track design tasks, update status, and handle workflows.
- Maintain a user-centered design approach and ensure designs follow best practices and accessibility guidelines.
- Communicate design ideas and prototypes to customers and team members.
- Participate in design critiques by sharing designs and giving feedback to teammates.
- Stay updated on design trends, techniques, and artificial intelligence developments.
- Adapt to a fast-paced environment and learn new tools and methods quickly.
- Attend and participate in team meetings and Scrum ceremonies.
- Experience designing supply chain, manufacturing, or operational analytics applications.
- Experience with HTML, CSS, and JavaScript to determine design feasibility.
- Experience with Scaled Agile Framework processes.
- Familiarity with React and AngularJS design constraints, responsive user interface principles, and collaboration with front-end teams.
- Understanding of Agile teams, practices, and principles.
- Deep understanding of data visualization and visual communication.
- Knowledge of creating and updating design components in Figma.
- Ability to plan immediate and incremental releases within a two-week sprint cadence.
- User experience design certification is optional.
- Agile-related certification is optional.
About the company
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $39.4 billion.
- Imdelltra sales jumped 219% year over year in Q1 2026, signaling rapid launch traction.
- Repatha sales rose 37% in Q2 2026, driven by expanding cardiology and primary-care adoption.
What critics are saying
- Prolia and Enbrel face accelerating biosimilar erosion; Amgen expects continued sales declines through 2026.
- Three distributors generated 77% of gross revenue in 2026, concentrating pricing leverage brutally.
- MariTide failure would crater obesity optionality and expose Amgen's growth to aging franchises.
What makes Amgen unique
- September 2026 Imdelltra-IMFINZI phase III hit overall survival in first-line ES-SCLC.
- August 2026 Repatha reduced death risk in high-risk patients, strengthening Amgen's cardiovascular moat.
- MariTide's monthly-or-less dosing and nine Phase III studies separate it from weekly GLP-1s.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.
Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.